Pfizer unveils $214M biotech plant

Pfizer has opened a new, $214 million biotech manufacturing facility in Sweden. The 68,000-square-foot plant will make recombinant proteins based on e. coli and yeast as well as a branded human growth hormone. But Pfizer says that it built the plant to accommodate the production of a variety of therapies. Report

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.